Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
Wild Times in NASH-Ville Part 3: Better Days ARE Ahead! Ep 28
Stephen Harrison leads the Surfers through a review of FGF-21s and other exciting drug development news.
Stephen Harrison starts this week's discussion reviewing the recent announcement of a promising Phase 1b/2a study for 89bio-100 (link to slide deck below), an FGF-21 agent that demonstrated significant reductions on liver fat and had positive effects on other metabolic measures. The discussion broadened to address an array of issues: other agents in development; changing (higher) expectations for how these agents will affect PDFF and possibly fibrosis; possible directions for combination therapy; and the five clinical values that collectively tell us the impact new medications can have on overall liver and metabolic health. One Surfer described this as a "brilliant 20-minute review."
89bio-slide deck: http://bit.ly/89bio-report